This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Von Hippel-Lindau Syndrome
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The goal of this clinical research study is to learn if pazopanib can help to control Von Hippel-Lindau Syndrome VHL. The safety of this drug will also be studied. This is an investigational study. Pazopanib is FDA approved and commercially available for kidney cancer. Its use to treat VHL is investigational. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pazopanib will be provided at no cost to you during this study. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.

Provided treatments

  • Drug: Pazopanib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01436227. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 32 volunteers for the current phase.
Official trial title:
A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome